NCT03677960View on ClinicalTrials.gov

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 17, 2018

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
HSIL, High-Grade Squamous Intraepithelial LesionsHuman Papilloma Virus InfectionHIV InfectionAnal CancerAnus Neoplasm
Interventions
DRUG

Topical ABI-1968 cream

Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29

Trial Locations (2)

2010

Research Center, Darlinghurst

60614

Research Center, Chicago

Sponsors

Lead Sponsor

Antiva Biosciences
All Listed Sponsors
lead

Antiva Biosciences

INDUSTRY

NCT03677960 - Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | Biotech Hunter | Biotech Hunter